Tonix Pharmaceuticals plans to conduct public offer of common stock

Roth and National Securities help finance development of TNX-102 SL

By Devika Patel

Knoxville, Tenn., Jan. 23 - Tonix Pharmaceuticals Holding Corp. said it will price a public sale of common stock.

Roth Capital Partners is the bookrunning manager, and National Securities Corp. is the co-manager.

Proceeds will be used for the development of TNX-102 SL, clinical trials of TNX-201, other development programs, product development and general corporate purposes.

Tonix is a specialty pharmaceutical company based in Zurich.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.